What's New Archives
- Slides of Dr. Youn Kim's presentation from the 65th Annual Meeting of the American Academy of Dermatology in Washington DC
- Great news! We now have another treatment that is available for our patients with cutaneous T-cell lymphoma (CTCL). The FDA approved Vorinostat (Zolinza) on 10/7/06 for treatment of cutaneous manifestations in patients with CTCL who have progressive, persistent, or recurrent disease on or following 2 systemic therapies. Vorinostat is a histone deacetylase inhibitor that is available as an oral agent and has shown response in patients with CTCL. Please contact your physician to discuss if you are a good candidate for this new therapy.
- New patient assistance program for patients on topical nitrogen mustard treatment
- Handouts from CTCL Forum of the Academy '06 in San Diego
- Handout from the 58th Annual Meeting of the Pacific Dermatologic Association
Navigation for This Section: Cutaneous Lymphoma
